Vioxx Importation On The Horizon? Health Canada Open To Rofecoxib Return
Executive Summary
Health Canada appears open to the reintroduction of Merck's COX-2 inhibitor Vioxx, Health Canada Manager of Marketed Pharmaceuticals Marc Berthiaume indicated during a July 7 media call
You may also be interested in...
“ALLHAT”-Type Cardio Safety Trial For COX-2s, NSAIDs Urged By FDA
FDA would like to see an "ALLHAT"-like study conducted with COX-2 inhibitors and non-selective NSAIDs to determine the relative gastrointestinal and cardiovascular safety of the two drug classes
Bextra, Vioxx Require Stronger Warnings, Additional Study, Cmte. Finds
Pfizer's Bextra requires additional clinical trials to clarify an observed cardiovascular signal, a joint FDA advisory committee on COX-2 inhibitor safety said
Celebrex Should Stay On Market, FDA Panel Says, But Splits On Vioxx, Bextra
Pfizer's COX-2 inhibitor Celebrex can remain on the market with new labeling warnings, including a "black box" about the increased risk of cardiovascular events, an FDA advisory committee recommended Feb. 18